ASX Announcements 2011
| 
| 
2012 |2011 | 2010 | 2009 | 2008 | 2007 |
DECEMBER 2011
20 December 2011 - Initial Director`s Interest Notice
19 December 2011 - Multiple Myeloma Trial Planning Underway
15 December 2011 - Suzy Jones Joins The Patrys Board
8 December 2011 - Notice Of Extraordinary General Meeting/Proxy Form 11/1/12
8 December 2011 - Section 708A Cleansing Statement
2 December 2011 - Patrys Announces Oversubscribed Capital Raising of AU$3.4M
2 December 2011 - Reinstatement To Official Quotation
1 December 2011 - Request From Suspension From Official Quotation
1 December 2011 - Suspension From Official QuotationNOVEMBER 2011
30 November 2011 - Results Of Meeting - AGM 2011
30 November 2011 - CEO's Presentation to AGM 2011
29 November 2011 - Trading Halt Request
29 November 2011 - Trading Halt
OCTOBER 2011
31 October 2011 - Appendix 4C-Quarterly Cash Flow Sept '11
28 October 2011 - Notice Of Annual General Meeting/ Proxy Form
19 October 2011 - Patrys' CEO Dr Marie Roskrow Joins The Board
19 October 2011 - Initial Director`s Interest Notice
17 October 2011 - Patrys Update On Large Scale Manufacturing Of PAT-SM6
10 October 2011 - CEO Investor Presentation
SEPTEMBER 2011
27 September 2011 - Significant Survival Benefit For PAT-SC1 Treated Patients
26 September 2011 - Annual Report To Shareholders
26 September 2011 - PAT-SM6 Shows Promise In Multiple Myeloma
20 September 2011 - PAT-SM6 Shows Promise In Additional Cancer Indications
19 September 2011 - Patrys Adds Second Clinical Centre For PAT-SM6 Trial
AUGUST 2011
30 August 2011 - Securities Trading Policy
26 August 2011 - Appendix 4E Preliminary Final Report
22 August 2011 - Patrys' PAT-SM6 Antibody Detected In Patient Tumours
17 August 2011 - Patrys Product Shows Promise In Multiple Myeloma
JULY 2011
25 July 2011 - Appendix 4C - Quarterly Cash Flow June 2011
25 July 2011 - Patrys Progresses PAT-SM6 Melanoma Trial
6 July 2011 - Change Of Substantial Holding
1 July 2011 - Final Director's Interest Notice
JUNE 2011
27 June 2011 - Patrys' PAT-SM6 Inhibits Metastases In Melanoma Cancer Model
22 June 2011 - Patrys CEO Interviews
20 June 2011 - Collaborations Support PAT-SM6 Clinical Program
2 June 2011 - New CEO Investor Presentation
MAY 2011
26 May 2011 - Patrys Confirms Clinical Status - Appoints New CEO
13 May 2011 - Agreement For PAT-LM1 Production Keeps Development on Track
APRIL 2011
19 April 2011 - Appendix 4C - Quarterly Cash Flow March 2011
13 April 2011 - Patrys Patents Allowed In Major Markets
MARCH 2011
22 March 2011 - Becoming A Substantial Holder
17 March 2011 - Patrys Receives Company Of The Year Award
11 March 2011 - Patrys Elects Closure Of Finance Facility
9 March 2011 - International Investor Update Presentation
9 March 2011 - Advances For PAT-SC1 Gastric Cancer Program
9 March 2011 - Change In Substantial Holding
9 March 2011 - Ceasing To Be A Substantial Holder
8 March 2011 - Biotech Industry’s Interest In PAT-SM6 Target Growing
8 March 2011 - Change Of Director's Interest Notice
FEBURARY 2011
23 Feburary 2011 - Half Year Report 2010
18 Feburary 2011 - Section 708A - Cleanisng Statement
18 Feburary 2011 - Appendix 3B
JANUARY 2011
28 January 2011 - Section 708A - Cleansing Statement
18 January 2011 - Appendix 4C - Quarterly Cash Flow December 2010
13 January 2011 - Issue Of Securities